Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
MAKING SENSE: A SCIENTIFIC APPROACH TO IV THERAPY
You have accessRestricted Access

Making Sense: A Scientific Approach to Intravenous Iron Therapy

David B. Van Wyck, Bo G. Danielson and George R. Aronoff
JASN December 2004, 15 (suppl 2) S91-S92; DOI: https://doi.org/10.1097/01.ASN.0000143813.03529.EC
David B. Van Wyck
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bo G. Danielson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George R. Aronoff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading

More than 100 yr have passed since parenteral iron was first given to humans (1). Fifty yr ago, carbohydrate was first coupled to iron oxide (2), reducing the fierce toxicity of ferric iron and introducing the era of parenteral therapy with carbohydrate-iron agents (3,4⇓). This is sufficient time to consider what we have learned about the risks and benefits of intravenous (IV) iron therapy; to review what we know and what we don’t; and, most important, to develop a comprehensive, unifying view that makes sense of the chemistry, biology, and pharmacology of IV iron agents.

Although treatment of iron deficiency certainly is not confined to patients with kidney disease, the majority of published evidence on IV iron therapy resides in the nephrology literature. Anemia is common among all patients with chronic kidney disease, expected among those with advanced kidney disease, and nearly universal among those who undergo dialysis. Evidence of iron deficiency is currently quite common in patients with chronic kidney disease–associated anemia (5). However, before treatment with erythropoietin receptor agonists (ERA; including epoetin α, epoetin β, and darbepoetin α), it was iron excess, not deficiency, that afflicted most dialysis patients. Because anemia was severe, transfusion dependence was common, and transfusional hemosiderosis resulted.

ERA therapy ended transfusion dependence, unmasked iron loss as the dominant feature of iron balance in hemodialysis patients, converted iron overload to iron deficiency as the prevailing disorder, highlighted the failure of oral iron supplementation to sustain iron sufficiency, and thereby thrust IV iron agents to the forefront of iron replacement. Two additional developments have heightened IV iron use in dialysis patients. The first is evidence that a maintenance IV iron schedule designed to prevent iron deficiency is more effective than a periodic treatment schedule in achieving target hemoglobin and minimizing doses of ERA therapy. The second is acceptance and implementation of anemia management guidelines, including those of the National Kidney Foundation Dialysis Outcomes Quality Initiative (K/DOQI) and European Best Practice Guidelines (EBPG). Publication of the first K/DOQI anemia guidelines in 1997 (6) and the EBPG anemia guidelines in 1999 (7) has been followed by gradual adoption of iron maintenance protocols. IV iron use in the United States has increased every year since 1996. By 2002, the proportion of patients who received IV iron within a single quarter approached 65%, and the average annual IV iron dose for all hemodialysis patients exceeded 2300 mg (8).

Increasing use of IV iron has prompted concerns for the potential hazards of iron therapy and the risks of iron overload and has stimulated a new and welcome wave of inquiry into iron safety. From in vitro studies to epidemiologic examination of large dialysis databases, evidence has accumulated rapidly. At the same time, new techniques to examine the structure and chemistry of iron carbohydrate compounds have helped to resolve decades-old controversies about how, for good or for bad, IV iron agents deliver biologically active iron.

A coherent, unifying view of IV iron agents, based soundly on an understanding of structure and chemistry, to encompass in vitro findings, explain in vivo observations, evaluate risks and benefits, and compare existing IV iron agents is urgently needed. During Renal Week in San Diego, California, in November 2003, Bo Danielson, George Aronoff, and David Van Wyck outlined one such view at a symposium sponsored and organized by the American Society of Nephrology. The current review arises from that collaboration. The groundbreaking work of Mary Cowman and Dina Kudasheva (9,10⇓) on carbohydrate-iron structure and chemistry plays a central role in formulating our review. The findings of these two colloid chemists make possible a remarkable synthesis of the chemistry, biology, and clinical use of IV iron agents.

Our conclusions are reassuring. No IV iron compounds generate detectable free iron. All IV iron agents release biologically available or labile iron. The rate of labile iron release in each agent is inversely related to the size of its iron core. The clinical consequences of labile iron release have little significance at low iron doses but limit the maximum tolerated single dose and rate of infusion of each IV iron agent. All evidence suggests that, in regard to iron release, IV iron use within current guidelines is safe and that K/DOQI limits for iron supplementation (11,12⇓) should continue to be observed.

  • © 2004 American Society of Nephrology

References

  1. ↵
    Stockman R: The treatment of chlorosis by iron and some other drugs. Br Med J 1: 881–885, 1893
    OpenUrlFREE Full Text
  2. ↵
    Nissim JA: Intravenous administration of iron. Lancet 1: 49–51, 1947
    OpenUrlPubMed
  3. ↵
    Fierz F: Contribution concerning the intravenous iron therapy. Investigations with Ferrum-Hausmann. Praxis 22: 469–472, 1950
    OpenUrl
  4. ↵
    Beutler E: The utilization of saccharated Fe59 oxide in red cell formation. J Lab Clin Med 51: 415–419, 1958
  5. ↵
    Hsu CY, McCulloch CE, Curhan GC: Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol 13: 2783–2786, 2002
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Eschbach JW, DeOreo P, Adamson J, Berns J, Biddle G, Comstock T, Jabs K, Lazarus JM, Nissenson AR, Stivelman J, Van Wyck DB, Wish J: NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 30: S192–S240, 1997
    OpenUrlPubMed
  7. ↵
    Barany P, Carrera F, Chanard J, Eckardt KU, Hadjicontantinou V, Leenaerts P, Leunissen ML, Locatelli F, MacLeod A, Rutkowski B, Sanz D, Schaefer RM, Schmieder R, Winearls CG: European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 14: 1–50, 1999
    OpenUrl
  8. ↵
    Wish JB, Johnson CA, Frankenfield DL: Intravenous iron use among adult hemodialysis (HD) patients: Results from the 2002 ESRD Clinical Performance (CPM) Project [Abstract]. J Am Soc Nephrol 14: 458A, 2003
    OpenUrl
  9. ↵
    Kudasheva DS, Lai J, Ulman A, Cowman MK: Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. J Inorgan Biochem 2004, in press
  10. ↵
    Kudasheva DS, Cowman MK: Structures of iron-carbohydrate complexes used as parenteral formulations [Abstract]. J Am Soc Nephrol 14: 856A, 2003
    OpenUrl
  11. ↵
    IV. NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis 37: S182–S238, 2001
    OpenUrlPubMed
  12. ↵
    Van Wyck DB: Lessons from NKF-DOQI: Iron management. Semin Nephrol 20: 330–334, 2000
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 15 (suppl 2)
Journal of the American Society of Nephrology
Vol. 15, Issue suppl 2
1 Dec 2004
  • Table of Contents
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Making Sense: A Scientific Approach to Intravenous Iron Therapy
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Making Sense: A Scientific Approach to Intravenous Iron Therapy
David B. Van Wyck, Bo G. Danielson, George R. Aronoff
JASN Dec 2004, 15 (suppl 2) S91-S92; DOI: 10.1097/01.ASN.0000143813.03529.EC

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Making Sense: A Scientific Approach to Intravenous Iron Therapy
David B. Van Wyck, Bo G. Danielson, George R. Aronoff
JASN Dec 2004, 15 (suppl 2) S91-S92; DOI: 10.1097/01.ASN.0000143813.03529.EC
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Labile Iron: Manifestations and Clinical Implications
  • Structure, Chemistry, and Pharmacokinetics of Intravenous Iron Agents
Show more MAKING SENSE: A SCIENTIFIC APPROACH TO IV THERAPY

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire